← back to search

David Allsop

Lancaster University · GB
Area of research
Physiology · Neurology
Research interest
Research interests include Alzheimer's disease research and treatments, Parkinson's Disease Mechanisms and Treatments, Prion Diseases and Protein Misfolding, and Cholinesterase and Neurodegenerative Diseases.
h-index
57
citations
15,420
works
215
NIH funding
primary concept
email

Recent publications

A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies.
2024cited by 15position: contributordoi
Liposome Nanoparticle Conjugation and Cell Penetrating Peptide Sequences (CPPs) Enhance the Cellular Delivery of the Tau Aggregation Inhibitor RI-AG03
2023cited by 0position: contributordoi
Oxidative Stress, Cytotoxic and Inflammatory Effects of Urban Ultrafine Road-Deposited Dust from the UK and Mexico in Human Epithelial Lung (Calu-3) Cells.
2022cited by 14position: contributordoi
Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.
2021cited by 21position: contributordoi
Variation in the concentration and regional distribution of magnetic nanoparticles in human brains, with and without Alzheimer's disease, from the UK.
2021cited by 18position: contributordoi
Cerebral spinal fluid biomarker profiles in CNS infection associated with HSV and VZV mimic patterns in Alzheimer's disease.
2021cited by 11position: contributordoi
Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens.
2020cited by 34position: contributordoi
Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis.
2020cited by 31position: contributordoi
Nabiximols for the Treatment of Cannabis Dependence
JAMA Internal Medicine 2019cited by 104position: middledoi
Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS.
2019cited by 51position: contributordoi
Plasma neurofilament light chain: A potential prognostic biomarker of dementia in adult Down syndrome patients.
2019cited by 26position: contributordoi
Clinical trials of medicinal cannabis for appetite‐related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation
Internal Medicine Journal 2016cited by 44position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 4 papers (2020–2024)Barbara A. Maher · Lancaster University2 papers (2021–2022)Jennifer Luksza · University of South Florida1 papers (2019–2019)Lawrence Lam · Macau University of Science and Technology1 papers (2016–2016) · 1 papers (2019–2019)Mark Montebello · The University of Sydney1 papers (2019–2019)Jessica Lee · New South Wales Department of Health1 papers (2016–2016)Nick Lintzeris · The University of Sydney1 papers (2016–2016)Meera Agar · University of Technology Sydney1 papers (2016–2016)Richard Chye · University of Technology Sydney1 papers (2016–2016)Nicholas Lintzeris · St. Leonards Hospital1 papers (2019–2019)Jan Copeland · UNSW Sydney1 papers (2019–2019)Adrienne Kirby · Nuffield Health1 papers (2019–2019)Melanie Lovell · The University of Sydney1 papers (2016–2016)Michelle Hall · New South Wales Department of Health1 papers (2019–2019) · 1 papers (2016–2016)Anthony Aggidis · Lancaster University1 papers (2024–2024)George Devitt · Southampton City Council1 papers (2024–2024)Francis L. Martin · Biocel UK Ltd1 papers (2020–2020)Francisco Bautista · Universidad Nacional Autónoma de México1 papers (2022–2022)